Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (28)
Maria Livia Del Giudice, Sara Galimberti & Gabriele Buda. (2023) Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents. Cancer Immunology, Immunotherapy 72:12, pages 3931-3937.
Crossref
Crossref
Luise Fischer, Nora Grieb, Uwe Platzbecker, Vladan Vucinic & Maximilian Merz. (2023)
CAR
T cell therapy in multiple myeloma, where are we now and where are we heading for?
. European Journal of Haematology.
Crossref
Crossref
Minghao Dang, Guangchun Han, Hans C. Lee, Krina K. Patel, Melody R. Becnel, Ruiping Wang, Sheeba K. Thomas, Dapeng Hao, Yanshuo Chu, Donna M. Weber, Pei Lin, Zuzana Lutter-Berka, David A. Berrios Nolasco, Mei Huang, Hima Bansal, Xingzhi Song, Jianhua Zhang, Andrew Futreal, Luz Yurany Moreno Rueda, David E. Symer, Michael R. Green, Cristhiam M. Rojas Hernandez, Michael Kroll, Vahid Afshar-Khargan, Libere J. Ndacayisaba, Peter Kuhn, Sattva S. Neelapu, Robert Z. Orlowski, Linghua Wang & Elisabet E. Manasanch. (2023) Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41:6, pages 1032-1047.e4.
Crossref
Crossref
Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tulin Budak-Alpdogan & Manoj K. Pandey. (2023) Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals 16:3, pages 415.
Crossref
Crossref
Mingming Zhang, Guoqing Wei, Linghui Zhou, Jincai Zhou, Siye Chen, Wei Zhang, Dongrui Wang, Xueping Luo, Jiazhen Cui, Simao Huang, Shan Fu, Xinkai Zhou, Yu Tang, Xiaomin Ding, Jiao Kuang, Xiaowen Peter He, Yongxian Hu & He Huang. (2023) GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. The Lancet Haematology 10:2, pages e107-e116.
Crossref
Crossref
Ajai ChariMonique C. MinnemaJesus G. BerdejaAlbert OriolNiels W.C.J. van de DonkPaula Rodríguez-OteroElham AskariMaría-Victoria MateosLuciano J. Costa, Jo CaersRaluca VeronaSuzette GirgisShiyi YangRachel B. GoldsmithXiang YaoKodandaram PillarisettiBrandi W. HilderJeffery RussellJenna D. GoldbergAmrita Krishnan. (2022) Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. New England Journal of Medicine 387:24, pages 2232-2244.
Crossref
Crossref
Scott R. Goldsmith, Shawn Streeter & Fahrettin Covut. (2022) Bispecific Antibodies for the Treatment of Multiple Myeloma. Current Hematologic Malignancy Reports 17:6, pages 286-297.
Crossref
Crossref
Sham MailankodySean M. DevlinJonathan LandaKarthik NathClaudia DiamonteElizabeth J. CarstensDouglas RussoRomany Auclair, Lisa FitzgeraldBriana CadzinXiuyan WangDevanjan SikderBrigitte SenechalVladimir P. BermudezTerence J. PurdonKinga HosszuDevin P. McAvoyTasmin FarzanaElena MeadJessica A. WilcoxBianca D. SantomassoGunjan L. ShahUrvi A. Shah, Neha KordeAlexander Lesokhin, Carlyn R. TanMalin HultcrantzHani HassounMikhail RoshalFiliz SenAhmet DoganOla LandgrenSergio A. GiraltJae H. ParkSaad Z. UsmaniIsabelle RivièreRenier J. BrentjensEric L. Smith. (2022) GPRC5D-Targeted CAR T Cells for Myeloma. New England Journal of Medicine 387:13, pages 1196-1206.
Crossref
Crossref
Arjun Lakshman & Shaji K. Kumar. (2021) Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update. American Journal of Hematology 97:1, pages 99-118.
Crossref
Crossref
Xiangmin Wang, Bin Pan, He Huang & Kailin Xu. (2021) Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma. ImmunoMedicine 1:2.
Crossref
Crossref
Linhe Wang, Jie Li, Shuai He, Yang Liu, Haitian Chen, Shujiao He, Meixian Yin, Dawei Zou, Shirui Chen, Tao Luo, Xinyu Yu, Xuesi Wan, Shunwei Huang, Zhiyong Guo & Xiaoshun He. (2021) Resolving the graft ischemia-reperfusion injury during liver transplantation at the single cell resolution. Cell Death & Disease 12:6.
Crossref
Crossref
Christie P. M. Verkleij, Marloes E. C. Broekmans, Mark van DuinKristine A. FrerichsRowan Kuiper, A. Vera de Jonge, Martin Kaiser, Gareth Morgan, Amy Axel, Rengasamy Boominathan, Jocelyn Sendecki, Amy Wong, Raluca I. Verona, Pieter SonneveldSonja ZweegmanHomer C. AdamsIIIIII, Tuna MutisNiels W. C. J. van de Donk. (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances 5:8, pages 2196-2215.
Crossref
Crossref
Faroogh Marofi, Safa Tahmasebi, Heshu Sulaiman Rahman, Denis Kaigorodov, Alexander Markov, Alexei Valerievich Yumashev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Rebar N. Mohammed, Mostafa Jarahian, Roza Motavalli & Farhad Motavalli Khiavi. (2021) Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Stem Cell Research & Therapy 12:1.
Crossref
Crossref
Andrew J. Cowan, Sherilyn A. Tuazon, Andrew J. Portuguese & Damian J. Green. (2021) Chimeric Antigen Receptor T Cells for Multiple Myeloma. The Cancer Journal 27:2, pages 112-118.
Crossref
Crossref
David Beauvais, Sophia Danhof, Patrick J. Hayden, Hermann Einsele & Ibrahim Yakoub-Agha. (2020) Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma. Current Opinion in Oncology 32:5, pages 418-426.
Crossref
Crossref
Fabian Freitag, Marius Maucher, Zeno Riester & Michael Hudecek. (2020) New targets and technologies for CAR-T cells. Current Opinion in Oncology 32:5, pages 510-517.
Crossref
Crossref
Luis Gerardo Rodríguez-Lobato, Maya Ganzetti, Carlos Fernández de Larrea, Michael Hudecek, Hermann Einsele & Sophia Danhof. (2020) CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Frontiers in Oncology 10.
Crossref
Crossref
Vishal Jindal, John Khoury, Ruby Gupta & Ishmael Jaiyesimi. (2020) Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma. American Journal of Clinical Oncology 43:5, pages 371-377.
Crossref
Crossref
Ewelina Grywalska, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Marcin Pasiarski, Paulina Niedźwiedzka-Rystwej & Jacek Roliński. (2020) Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells 9:4, pages 983.
Crossref
Crossref
He Huang, Heng-wei Wu & Yong-xian Hu. (2019) Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma嵌合抗原受体 T 细胞在治疗难治/复发多发性骨髓瘤中的新进展. Journal of Zhejiang University-SCIENCE B 21:1, pages 29-41.
Crossref
Crossref
Urvi A. Shah & Sham Mailankody. (2020) CAR T and CAR NK cells in multiple myeloma: Expanding the targets. Best Practice & Research Clinical Haematology, pages 101141.
Crossref
Crossref
Carlos Fernandez de Larrea, Sham Mailankody, Ola Landgren & Eric L. Smith. (2019) Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma. ADVANCES IN CELL AND GENE THERAPY 3:1.
Crossref
Crossref
Chao Wu, Lina Zhang, Qierra R. Brockman, Fenghuang Zhan & Lijuan Chen. (2019) Chimeric antigen receptor T cell therapies for multiple myeloma. Journal of Hematology & Oncology 12:1.
Crossref
Crossref
Deepu Madduri, Madhav V. Dhodapkar, Sagar Lonial, Sundar Jagannath & Hearn Jay Cho. (2019) SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents. Clinical Lymphoma Myeloma and Leukemia 19:9, pages 537-544.
Crossref
Crossref
Urvi A. Shah & Eric L. Smith. (2019) Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells. The Cancer Journal 25:3, pages 208-216.
Crossref
Crossref
Eric L. Smith, Kim HarringtonMette Staehr, Reed Masakayan, Jon Jones, Thomas J. LongKhong Y. Ng, Majid Ghoddusi, Terence J. PurdonXiuyan WangTrevor DoMinh Thu PhamJessica M. Brown, Carlos Fernandez De LarreaEric OlsonElizabeth Peguero, Pei WangHong LiuYiyang XuSarah C. Garrett-Thomson, Steven C. AlmoHans-Guido Wendel, Isabelle RiviereCheng LiuBlythe Sather & Renier J. Brentjens. (2019) GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine 11:485.
Crossref
Crossref
Mingjuan Jin, Simeng Gu, Ding Ye, Yingjun Li, Fangyuan Jing, Qilong Li & Kun Chen. (2017)
Association between genetic variants in the promoter region of a novel antisense long noncoding RNA
RP11-392P7.6
and colorectal cancer risk
. Environmental and Molecular Mutagenesis 58:6, pages 434-442.
Crossref
Crossref
Yossi Cohen, Odit Gutwein, Osnat Garach-Jehoshua, Adina Bar-Haim & Abraham Kornberg. (2014) Bone Marrow Expression of CCL3 Is Not Correlated with the Extent of Lytic Bone Lesions. Acta Haematologica 132:2, pages 129-133.
Crossref
Crossref